(RTTNews) - Shares of MorphoSys AG (MOR) are down more than 12% Wednesday morning. The acquisition adds two mid-to-late stage product candidates, CPI-0610 and CPI-0209 to MorphoSys' pipeline. MorphoSys also announced that it has entered into a long-term strategic funding partnership with Royalty Pharma plc (RPRX), that will help the company to fund the transaction along with other benefits.